Editorials

Who benefits from Helicobacter pylori eradication?

BMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7535.187 (Published 26 January 2006) Cite this as: BMJ 2006;332:187
  1. Brendan C Delaney, professor of primary care ([email protected])
  1. University of Birmingham, Edgbaston, Birmingham B15 2TT

    Mainly patients with endoscopically proved peptic ulcer or functional dyspepsia

    Dyspepsia has most recently been defined as predominant epigastric pain present for at least four weeks, with or without heartburn.1 By implication gastro-oesophageal reflux disease (GORD) refers to predominant heartburn. These definitions work reasonably well when peptic ulcer has been excluded by endoscopy, but they fail to be sufficiently predictive in uninvestigated patients.2 Thus the guideline on dyspepsia produced by the National Institute for Health and Clinical Excellence (NICE) in 2004 recommended a common pathway for investigating and treating previously uninvestigated patients who had both heartburn and epigastric pain.3 Patients who have had endoscopy can be categorised according to the cause found—peptic ulcer, oesophagitis, or no obvious cause (functional dyspepsia or functional heartburn).

    Eradication of Helicobacter pylori is most effective in preventing the recurrence of duodenal ulcer: the number needed to treat (NNT) for preventing one recurrence of ulceration at one year is 2.4 It now seems naive to have expected such effectiveness of eradication in other conditions related to dyspepsia, but undue optimism has led to several underpowered randomised controlled trials, particularly on functional …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe